207 related articles for article (PubMed ID: 33674736)
1. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
Yao S; Janku F; Subbiah V; Stewart J; Patel SP; Kaseb A; Westin SN; Naing A; Tsimberidou AM; Hong D; Piha-Paul SA; Shi N; Johnston A; Bomalaski J; Fu S
Br J Cancer; 2021 Apr; 124(9):1533-1539. PubMed ID: 33674736
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW
Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035
[TBL] [Abstract][Full Text] [Related]
3. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
Yao S; Janku F; Koenig K; Tsimberidou AM; Piha-Paul SA; Shi N; Stewart J; Johnston A; Bomalaski J; Meric-Bernstam F; Fu S
Cancer Med; 2022 Jan; 11(2):340-347. PubMed ID: 34841717
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Beddowes E; Spicer J; Chan PY; Khadeir R; Corbacho JG; Repana D; Steele JP; Schmid P; Szyszko T; Cook G; Diaz M; Feng X; Johnston A; Thomson J; Sheaff M; Wu BW; Bomalaski J; Pacey S; Szlosarek PW
J Clin Oncol; 2017 Jun; 35(16):1778-1785. PubMed ID: 28388291
[TBL] [Abstract][Full Text] [Related]
8. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
[TBL] [Abstract][Full Text] [Related]
10. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
11. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
12. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
[TBL] [Abstract][Full Text] [Related]
13. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
14. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Harding JJ; Yang TS; Chen YY; Feng YH; Yen CJ; Ho CL; Huang WT; El Dika I; Akce M; Tan B; Cohen SA; Meyer T; Sarker D; Lee DW; Ryoo BY; Lim HY; Johnston A; Bomalaski JS; O'Reilly EM; Qin S; Abou-Alfa GK
Cancer; 2021 Dec; 127(24):4585-4593. PubMed ID: 34415578
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
Tsai HJ; Jiang SS; Hung WC; Borthakur G; Lin SF; Pemmaraju N; Jabbour E; Bomalaski JS; Chen YP; Hsiao HH; Wang MC; Kuo CY; Chang H; Yeh SP; Cortes J; Chen LT; Chen TY
Sci Rep; 2017 Sep; 7(1):11253. PubMed ID: 28900115
[TBL] [Abstract][Full Text] [Related]
18. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
19. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
20. The Citrulline Recycling Pathway Sustains Cardiovascular Function in Arginine-Depleted Healthy Mice, but Cannot Sustain Nitric Oxide Production during Endotoxin Challenge.
Yuan Y; Mohammad MA; Betancourt A; Didelija IC; Yallampalli C; Marini JC
J Nutr; 2018 Jun; 148(6):844-850. PubMed ID: 29878271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
